Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRB3 | P28472 | 2/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 3/20 | 0.31 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6906160 | 0.80 | TACR1 (0.35) | ALDH1A1TACR1KCNN4 | |
| SCHEMBL6899145 | 0.79 | GABRP (0.37) | GABRB3NOTUMGABRA2GABRB2ALDH1A1 | |
| SCHEMBL6903632 | 0.79 | NOTUM (0.33) | NOTUMMEN1KMT2AHSD11B1 | |
| SCHEMBL6906733 | 0.79 | MEN1 (0.30) | MEN1KMT2ATACR1 | |
| SCHEMBL6918745 | 0.71 | HSD17B10 (0.35) | MEN1KMT2ATACR1 | |
| SCHEMBL6920360 | 0.68 | TACR1 (0.36) | TACR1 | |
| SCHEMBL8705898 | 0.66 | NOTUM (0.48) | NOTUMMEN1KMT2AALDH1A1TACR1 | |
| SCHEMBL4205517 | 0.65 | KCNN4 (0.56) | MEN1KMT2AALDH1A1TACR1KCNN4 | |
| SCHEMBL2658853 | 0.65 | L3MBTL1 (0.41) | NOTUMALDH1A1KCNN4P2RX7L3MBTL1 | |
| SCHEMBL5781675 | 0.64 | ALDH1A1 (0.45) | KMT2AALDH1A1L3MBTL1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220403-A1 | 1-(2-Methoxybenzyl)-3-benzhydrylpiperazines as tachykinin anatgonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220403-A1 | 1-(2-Methoxybenzyl)-3-benzhydrylpiperazines as tachykinin anatgonists | BDKRB1, BDKRB2, TACR1 | GABRB3 675/4885NOTUM 3732/4885MEN1 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.